Globus Medical (NYSE:GMED – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.950-5.050 for the period, compared to the consensus EPS estimate of 5.000. The company issued revenue guidance of $3.1 billion, compared to the consensus revenue estimate of $3.2 billion.
Globus Medical Stock Down 6.9%
Shares of NYSE:GMED traded down $5.97 on Thursday, reaching $81.13. The company had a trading volume of 3,034,249 shares, compared to its average volume of 1,474,554. Globus Medical has a twelve month low of $60.36 and a twelve month high of $101.40. The stock has a 50-day moving average price of $77.48 and a 200 day moving average price of $83.35. The stock has a market capitalization of $10.89 billion, a P/E ratio of 20.75, a P/E/G ratio of 1.28 and a beta of 0.98.
Globus Medical (NYSE:GMED – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The business had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. During the same period last year, the business posted $0.86 EPS. Globus Medical’s revenue was up 5.9% compared to the same quarter last year. On average, sell-side analysts predict that Globus Medical will post 4.99 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on GMED. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. UBS Group initiated coverage on shares of Globus Medical in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price target on the stock. BMO Capital Markets started coverage on shares of Globus Medical in a report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price for the company. Finally, Truist Financial lowered their price objective on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and an average target price of $99.46.
Get Our Latest Research Report on Globus Medical
Insider Activity
In related news, Director Stephen T. Zarrilli sold 25,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares in the company, valued at $2,176,000. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James Tobin sold 30,000 shares of Globus Medical stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the sale, the director directly owned 15,000 shares in the company, valued at $1,118,700. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 18.38% of the company’s stock.
Globus Medical Company Profile
Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.
Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.
Featured Stories
- Five stocks we like better than Globus Medical
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
